A kidney disease therapy from Vertex is under intensified scrutiny for infection risk ahead of an FDA approval decision, according to the report. The focus is on how the potential safety profile could affect prescriber adoption and patient selection in a setting where infections are a key concern. For stakeholders awaiting a regulatory call, the near-term market impact will depend on whether the FDA’s assessment results in labeling that changes monitoring requirements, contraindications, or risk mitigation plans.